drugset / Trial / NCT00003483

Antineoplaston Therapy in Treating Patients With Meningioma

NCT00003483

Phase 2 Terminated 3 enrolled Burzynski Research Institute
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Current therapies for adults with meningioma provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of adults with meningioma. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on adults with meningioma.

Timeline

Start
1998-06
Primary completion
2004-03
Completion
2004-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Astugenal Unknown Intravenous
Subject antineoplaston A10 Small molecule Intravenous

Indications